ADP Sets the Record Straight and Addresses Pershing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
117
ADP Sets the Record Straight and Addresses Pershing Square's False and Misleading Claims With Facts

ROSELAND, NJ--(Marketwired - Nov 1, 2017) - ADP ( NASDAQ : ADP ) today issued the following statement:

ADP's Annual Meeting of Stockholders is rapidly approaching on November 7. The Company urges all ADP stockholders to protect the value of their investment by voting online or by phone today using the WHITE proxy card in support of ADP's 10 highly qualified directors.

Throughout this proxy contest, Pershing Square has continued to distort the facts and mislead the investing public in an attempt to discredit ADP. ADP strongly rejects the false and reckless claims made by Pershing Square's Bill Ackman, and believes it is imperative to set the record straight for investors.

Pershing Square Claims Vs. ADP Facts

Claim: ADP initiated the proxy fight.

Fact: Bill Ackman first contacted ADP with a phone call on August 1 -- only nine days before ADP's nomination deadline -- requesting an extension for the nomination deadline, and stating that he planned to nominate five directors, including himself, to ADP's 10-member Board of Directors. He also said CEO Carlos Rodriguez should be replaced. The full Board offered to meet before August 10, but Mr. Ackman declined because he said he wasn't ready with his presentation, and in any case, he was leaving on a vacation on the evening of August 3.

* * *

Claim: Pershing Square owns 8.3% of ADP's common stock . 

Fact : Pershing Square announced an economic stake of 8.3% in August, the vast majority of which is held in derivatives, which cannot be voted at the upcoming meeting. In actual fact, as of the record date, Pershing Square owns only about 2% of ADP's common stock and can only vote those shares. 

* * *

Claim: CDK's margins are higher than ADP's and demonstrate that ADP is underachieving its margin expansion opportunity.

Fact: Margin comparisons between ADP and CDK Global are misleading. In its adjusted margin calculation, CDK excludes stock compensation, depreciation and amortization, and transformation expenses -- all of which are included in ADP's adjusted EBIT margin. When the two companies' FY 2017 margins are analyzed on a comparable basis by excluding pass-throughs, ADP's adjusted EBIT margin is actually 200 basis points higher than CDK's.

* * *

Claim: "Operational Margins" do not appropriately capture ADP profitability.

Fact: ADP's approach to calculating operational margin contribution is the most relevant way to assess progress in ADP's business. ADP expects operational margin contribution to adjusted EBIT margin of 500 basis points from FY 2017 to FY 2020. Isolating the impact of PEO pass-throughs and client funds on adjusted EBIT margin is consistent with margin disclosures historically provided in ADP's financial results and guidance, and best captures progress in ADP's underlying operations

* * *

Claim: ADP has lost thousands of Enterprise clients to competitors.

Fact: ADP's Enterprise client count between FY 2009 and FY 2017 has remained largely consistent and ADP's overall client retention has remained above 90% every year since FY 2011. ADP has also gained client share across every major category of the HCM market in which it competes, from FY2011 through FY2017.

* * *

Claim: ADP's labor productivity is flat.

Fact: ADP's investments in technology and service have resulted in ongoing productivity gains. From FY 2011 to FY 2017, ADP's gross revenue per full-time employee grew at a 2% compound annual growth rate (CAGR) to $215,000, and adjusted EBIT per full-time employee, excluding client funds, grew at a 7% CAGR. Additionally, new business bookings have increased at a 7% CAGR from FY 2011 to FY 2017 while ADP's sales force only grew at a 4% CAGR over the same period.

* * *

Claim: ADP's technology is outdated and not competitive.

Fact: 83% of ADP clients are on cloud-based strategic platforms and ADP shifted its strategy to primarily focus on organic, innovation-driven growth and increased investment in R&D innovation from $150 million in FY 2011 to $450 million in FY 2017, a 20% CAGR.

* * *

Claim: ADP is not committed to reducing spend on legacy products.

Fact: ADP has retired/divested 13 major legacy platforms since FY 2011. During this period, ADP has shifted spend on innovation from 28% to 52% of its total R&D investment.

* * *

Claim: ADP has too many real estate locations and a sprawling and subscale current service structure.

Fact: ADP has consolidated 29 net operations locations in FY 2017 (55% of total planned exits) as part of its Service Alignment Initiative.

* * *

Claim: ADP's Total Shareholder Return (TSR) is overstated.

Fact: ADP's TSR has consistently outperformed the market. Since November 9, 2011, ADP has generated TSR of 203%, compared to the S&P 500 at 128% and its HCM peer companies at 153%. ADP also has outperformed the S&P 500 over 1-, 3-, and 5-year periods, and has returned $11.3 billion of cash to its shareholders since FY 2011 through dividends and share repurchases.

* * *

Claim: ADP's Board is stale and needs fresh perspectives.

Fact: ADP has a deliberate program of refreshment to achieve a balance of leadership continuity and fresh perspectives -- since 2014 ADP has added four new independent Directors with additive skills aligned to ADP's strategy. The Board's average tenure as of the Annual Meeting is 6.8 years, well below the S&P 500 average of 8.3 years.

* * *

Claim: ADP's Board does not have the right talent.

Fact: ADP's Directors have a deep understanding of the HCM marketplace and ADP's competitive position. Seven of 10 Directors are current or former CEOs, CFOs, or COOs of major public companies. A number of Directors have significant technology experience and broad strategic planning and international expertise.

Investors are encouraged to review ADP's investor presentation for a comprehensive view of the company's strategy, management's strong execution and the Board's proactive stewardship. The presentation and other helpful materials are publicly available on ADP's Investor Relations website and at www.VoteADP.com .

Your vote requires an important decision about whether ADP has the right Board and the right strategy. ADP urges shareholders to protect their investment and vote using the WHITE proxy card to re-elect all of the Company's 10 highly qualified and experienced directors.

Time is Short. Please vote today online or by phone by following the directions on your WHITE proxy card. If you have questions, or need assistance in voting your shares, please contact: INNISFREE M&A INCORPORATED Shareholders Call Toll-Free: (877) 750-0510 Banks and Brokers Call Collect: (212) 750-5833 REMEMBER: Discard any Gold proxy card that you may receive from Pershing Square. Returning a Gold proxy card -- even if you "withhold" on Pershing Square's nominees -- will revoke any vote you had previously submitted on ADP's WHITE proxy card.

About ADP ( NASDAQ : ADP ) Powerful technology plus a human touch. Companies of all types and sizes around the world rely on ADP cloud software and expert insights to help unlock the potential of their people. HR. Talent. Benefits. Payroll. Compliance. Working together to build a better workforce. For more information, visit ADP.com.

ADP, the ADP logo and ADP A more human resource are registered trademarks of ADP, LLC. All other marks are the property of their respective owners.

Copyright © 2017 ADP, LLC. All rights reserved.

ADP-Media

SAFE HARBOR STATEMENT This document and other written or oral statements made from time to time by ADP may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical in nature and which may be identified by the use of words like "expects," "assumes," "projects," "anticipates," "estimates," "we believe," "could," "is designed to" and other words of similar meaning, are forward-looking statements. These statements are based on management's expectations and assumptions and depend upon or refer to future events or conditions and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed. Factors that could cause actual results to differ materially from those contemplated by the forward-looking statements or that could contribute to such difference include: ADP's success in obtaining and retaining clients, and selling additional services to clients; the pricing of products and services; compliance with existing or new legislation or regulations; changes in, or interpretations of, existing legislation or regulations; overall market, political and economic conditions, including interest rate and foreign currency trends; competitive conditions; our ability to maintain our current credit ratings and the impact on our funding costs and profitability; security or privacy breaches, fraudulent acts, and system interruptions and failures; employment and wage levels; changes in technology; availability of skilled technical associates; and the impact of new acquisitions and divestitures. ADP disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These risks and uncertainties, along with the risk factors discussed under "Item 1A. - Risk Factors" in our Annual Report on Form 10-K should be considered in evaluating any forward-looking statements contained herein.

ADDITIONAL INFORMATION ADP, its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from Company shareholders in connection with the matters to be considered at the Company's 2017 Annual Meeting. The Company has filed a definitive proxy statement and WHITE proxy card with the U.S. Securities and Exchange Commission (the "SEC") in connection with any such solicitation of proxies from Company shareholders. COMPANY SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT AND ACCOMPANYING WHITE PROXY CARD AS THEY CONTAIN IMPORTANT INFORMATION. Information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, is set forth in the proxy statement and other materials to be filed with the SEC. Shareholders will be able to obtain any proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC for no charge at the SEC's website at www.sec.gov . The proxy statement and other relevant documents filed by ADP with the SEC are also available, without charge, by directing a request to ADP's proxy solicitor, Innisfree M&A Incorporated, 501 Madison Avenue, 20th Floor, New York, New York 10022; call toll-free:(877) 750-0510 or call collect: (212) 750-5833.Copies will also be available at no charge at the Company's website at www.adp.com .

CONTACTS : Investors: Christian Greyenbuhl (973) 974-7835 Christian.Greyenbuhl@adp.com Byron Stephen (973) 974-7896 Byron.Stephen@adp.com Media: Michael Schneider (973) 974-5678 office (973) 868-1000 mobile Michael.Schneider@adp.com George Sard/Jared Levy/Liz Zale Sard Verbinnen & Co (212) 687-8080 ADP-SVC@sardverb.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 50

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 84

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Equitage Ventures Launches $47.3M Fund for Senior Care Tech

Updated Category News Views 329

Equitage Ventures Launches Significant Investment Fund Equitage Ventures, an early-stage venture capital firm dedicated to AgeTech, has announced the successful final closing of a substantial $47.3 million investment fund. This fund is designed to provide critical capital, distribution resources, and strategic guidance to innovative entrepreneurs who aim to tackle the...

Continue Reading
Understanding Market Trends: Insights into Chevron Corp's Performance

Updated Category News Views 171

Chevron Corp Market Sentiment Analysis Chevron Corp (NYSE: CVX) has experienced a noteworthy decline in its short interest as a percentage of float, showing a 10.26% decrease since its previous report. Currently, there are approximately 14.02 million shares sold short, which accounts for 0.7% of all shares available for trading. Given the trading volume, it is estimated...

Continue Reading
Establishment of Blakely McCrory Hope Fund at Moody Gardens

Updated Category News Views 200

Introducing the Blakely McCrory Hope Fund Moody Gardens is proud to announce a special initiative to honor the memory of a young girl who captured the hearts of many: the Blakely McCrory Hope Fund. This fund has been established in loving memory of 8-year-old Blakely McCrory, who lost her life in a tragic flooding incident that occurred during the summer months....

Continue Reading
Star-Studded Table Read of 'It's a Wonderful Life' Event

Updated Category News Views 221

Exciting Holiday Table Read for a Worthy Cause The Ed Asner Family Center is pulling out all the stops this holiday season with an exciting virtual table read of the beloved classic, "It's a Wonderful Life." Scheduled for December 14 at 5 PM PST, this event promises to spread joy while supporting individuals and families with special needs. Star-Studded Cast Comes...

Continue Reading
Transforming $100 Into Over $1700 with Monolithic Power Systems

Updated Category News Views 145

Understanding the Growth of Monolithic Power Systems Monolithic Power Systems (NASDAQ: MPWR) has showcased impressive financial performance over the past decade, outperforming many market benchmarks. With an impressive annualized growth rate of 19.88%, it has attracted the attention of savvy investors. The Power of Compounded Returns Imagine investing $100 in MPWR stock...

Continue Reading